Sucampo Seeks Additional FDA Approvals
Sucampo Pharmaceuticals, a Bethesda drugmaker that went public last month, announced today that the Food and Drug Administration has accepted the firm's application seeking additional approval of its treatment for constipation. See the company's release.
Sucampo last year received approval from the FDA to market Amitiza, a treatment for chronic constipation. The company is now asking the agency for permission to use the drug in smaller doses to treat irritable bowel syndrome. Prescriptions for Amitiza, formally known as lubiprostone, produced $9.6 million in royalties for the company in the quarter ending June 30, according to company filings.
Founded in 1996 by by biochemists Sachiko Kuno and Ryuji Ueno, Sucampo raised more than $28 million with its initial public offering. The company is building its future around drugs derived from human fatty acids called prostones, from which it hopes to develop treatments for a broad range of diseases, including vascular and central nervous system ailments.
Please email us to report offensive comments.
The comments to this entry are closed.